ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1655

Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation
Abstract Number: 1656

Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
Abstract Number: 1657

Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models
Abstract Number: 1658

Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1659

Prevalence and Progression of Multimorbidity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1660

Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial
Abstract Number: 1661

Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 1662

Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
Abstract Number: 1663

Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
Abstract Number: 1664

Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Abstract Number: 1665

Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
Abstract Number: 1666

Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
Abstract Number: 1667

Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
Abstract Number: 1668

A clinically validated assay for rapid determination of type I and type II interferon activity in pediatric inflammatory diseases
Abstract Number: 1669

Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].